CNBX - Cannabics Pharma posts positive interim results from RCC-33 cancer study in mice

Cannabics Pharma ([[CNBX]] +9.7%)  has obtained positive interim results for its ongoing in-vivo study evaluating the efficacy of the company's RCC-33 for colorectal cancer in nude-mice.The interim results show a 27% reduction in tumor volume in mice exposed to RCC-33 in comparison with sham control mice, the company said, adding that the study is ongoing.Differences in tumor volume between the two groups were first observed after 5 days of treatment with interim results of a 27% reduction in tumor volume being observed after 12 days of treatment, with p-value=0.022.

For further details see:

Cannabics Pharma posts positive interim results from RCC-33 cancer study in mice